The use of SPEctroscopy during Endoscopy for Detection of PANcreatic Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON28590

Enrollment

Registered

2019-03-18

Start date

2019-03-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: - Patients scheduled for EUS-FNA, due to a suspect lesion of the pancreas - Patients with a minimum age of 18 years

Exclusion criteria

Exclusion criteria: - Patients who object to participate in this study.

Design outcomes

Primary

Measure	Time frame
The ability of SFR spectroscopy incorporated in EUS-FNA procedure in distinguishing benign and malignant pancreatic tissue by measuring wavelength dependent optical characteristics over a broad wavelength range (400-1000 nm).	—

Secondary

Measure	Time frame
Selection of wavelengths specific for pancreatic tumor detection and evaluation of its diagnostic accuracy compared to cytological diagnosis.	—

Contacts

Public ContactJ.S.D. Mieog

Leiden University Medical Center

j.s.d.mieog@lumc.nl31 71 529 9143

Outcome results